Tapentadol Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Tapentadol Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
169
Registered trials
52
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Tapentadol Hydrochloride can convert its Small molecule drug profile and NET x μ opioid receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Tapentadol Hydrochloride (query alias: tapentadol) |
|---|---|
| Modality / target | Small molecule drug; NET x μ opioid receptor; NET inhibitors, μ opioid receptor agonists |
| Highest global status | Approved |
| Originator | Janssen Global Services LLC |
| Active developers | Grünenthal GmbH, Jiangsu Huatai Chenguang Pharmaceutical Co., Ltd., ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT Co Ltd |
The MCP disease footprint includes Cancer Pain, Neuralgia, Chronic Pain. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07320781 | Not Applicable | Completed | 70 | Intraoperative and postoperative morphine consumption |
| CTR20261574 | Not Applicable | 进行中 （招募中） | 48 | Not disclosed |
| NCT07587645 | Not Applicable | Completed | 46 | Pain intensity by Numeric Rating Scale (NRS) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Phase 4 Study of Tapentadol vs Oxycodone in Neuropathic Pain
Phase 4; n=3; evaluation: not stated. Reported fields: -; V1(Mean) = 2.6 Z-score (Full Range, 2.2 - 3); -
OBSERVATIONAL PROSPECTIVE COHORT STUDY TO EVALUATE EFFICACY AND SAFETY OF TAPENTADOL IN PATIENTS WITH RESPIRATORY DISEASE
Not Applicable; n=29; evaluation: Positive. Reported fields: Basal oxygen saturation = 96 %
1202 - Analgesic efficacy in Head and neck cancer patients using tapentadol vs. tramadol plus paracetamol
Not Applicable; n=60; evaluation: Positive. Reported fields: Adverse Event: Emesis = 5 patients did not tolerate due to emesis and sedation, in spite of good pain relief; these 5 patients were switched to morphine 10mg 4th hourly. ; Adverse Event: Emesis = 5 patients did not tolerate due to emesis and sedation, in spite of good pain relief; these 5 patients were switched to morphine 10mg 4th hourly. ; Adverse Event: Emesis = 5 patients did not tolerate due to emesis and sedation, in spite of good pain relief; these 5 patients were switched to morphine 10mg 4th hourly.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Tapentadol Hydrochloride addresses Cancer Pain, Neuralgia, Chronic Pain. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-04-29 | Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER | Approved | Financial terms not disclosed |
| 2018-01-10 | Collegium Pharmaceutical purchases Assertio's NUCYNTA product franchise. | Approved | US$10.0M upfront; US$375.0M stated total |
| 2010-06-07 | Janssen Pharmaceutica N.V. Announces Expansion of Licensing Agreement for Tapentadol (NUCYNTA® /PALEXIA® /PALEXIS®) | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Methods, systems, and compositions related to use of mu opioid receptor (MOR) antagonists”. The milestone feed surfaced a patent-application signal described as “Method for preparing tapentadol or pharmaceutically acceptable salt thereof through continuous flow reaction”. The milestone feed surfaced a patent-application signal described as “Method for preparing tapentadol or medicinal salt thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
